Business Context and Reporting Period
This Form 8-K was filed by AcelRx Pharmaceuticals, Inc. (not Talpher, Inc.) on May 8, 2019. The filing serves to announce the company's financial results for the three months ended March 31, 2019. The company is incorporated in Delaware and trades on the Nasdaq Global Market under the symbol ACRX.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document explicitly states that the detailed financial results are contained in a press release furnished as Exhibit 99.1, which is not included in the input text.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. It only references the issuance of a press release containing the results for the quarter ended March 31, 2019.
Guidance, Outlook, and Risks
The filing includes a standard legal disclaimer stating that the information in Item 2.02 and Exhibit 99.1 is "furnished" and not "filed" for purposes of Section 18 of the Exchange Act. Consequently, this information is not subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act and will not be incorporated by reference into other filings unless expressly stated. No specific guidance, outlook, or risk factors are detailed in the text of this 8-K.
Investor Verification Checklist
- Verify the specific financial figures (revenue, net loss, cash position) by reviewing Exhibit 99.1 (Press Release dated May 8, 2019), as they are absent from the 8-K text.
- Confirm the company name is AcelRx Pharmaceuticals, Inc. (ACRX), noting the discrepancy with the metadata field "TALPHERA, INC."
- Review the full press release for any forward-looking statements or operational updates not captured in this summary.
- Check subsequent filings for any updates to the financial condition reported for the quarter ended March 31, 2019.